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Abstract Quantitative multistage carcinogenesis models
are used in radiobiology to estimate cancer risks and
latency periods (time from exposure to clinical cancer).
Steps such as initiation, promotion and transformation have
been modeled in detail. However, progression, a later step
during which malignant cells can develop into clinical
symptomatic cancer, has often been approximated simply
as a ﬁxed lag time. This approach discounts important
stochastic mechanisms in progression and evidence on the
high prevalence of dormant tumors. Modeling progression
more accurately is therefore important for risk assessment.
Unlike models of earlier steps, progression models can
readily utilize not only experimental and epidemiological
data but also clinical data such as the results of modern
screening and imaging. Here, a stochastic progression
model is presented. We describe, with minimal parame-
terization: the initial growth or extinction of a malignant
clone after formation of a malignant cell; the likely dor-
mancy caused, for example, by nutrient and oxygen
deprivation; and possible escape from dormancy resulting
in a clinical cancer. It is shown, using cohort simulations
with parameters appropriate for lung adenocarcinomas, that
incorporating such processes can dramatically lengthen
predicted latency periods. Such long latency periods
together with data on timing of radiation-induced cancers
suggest that radiation may inﬂuence progression itself.
Introduction
The importance of tumor progression
Tumor progression is a late step in carcinogenesis, during
which previously transformed, neoplastic cells may pro-
liferate, become more malignant and evolve into cancer
that presents the ﬁrst clinical symptoms. In radiation risk-
estimation, early steps such as initiation, promotion and
transformation have been extensively investigated (Lue-
beck and Hazelton 2002; Moolgavkar and Luebeck 2003;
Sachs et al. 2005; Heidenreich et al. 2007; Little et al.
2008). Progression, however, has as yet received less
attention. Indeed, current quantitative radiobiology models
often approximate progression as merely a ﬁxed time lag
from the appearance of the ﬁrst malignant cell until clinical
cancer incidence.
This deterministic ﬁxed lag time approximation over-
looks important mechanisms underlying progression,
which may signiﬁcantly affect risk assessment. After
transformation has produced a malignant cell, this lesion
needs to progress through various phases before reaching a
clinical stage. First, it needs to escape extinction in a sto-
chastic birth–death proliferation process. If the lesion does
start to expand, immune suppression or lack of neo-vas-
cularization may arrest or drastically slow its clone’s
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Ghiso 2007; Kim et al. 2007; Koebel et al. 2007). A sub-
sequent switch from the dormancy phase to aggressive
proliferation may take years or even be postponed indeﬁ-
nitely (Naumov et al. 2008). Hence, progression duration
may be a major part of the latency period between radiation
and clinical cancer.
The effects of stochastic proliferation of malignant
lesions has been addressed and discussed in various ways
but quantitative analyses have been limited to theoretical
formalisms or to modeling rodent experiments (Dewanji
et al. 1991; Yang and Chen 1991; Luebeck and Moolgav-
kar 1994; Tan and Chen 1998; Smith and Portier 2000).
Recently, we analyzed the effect of stochastic extinction on
progression distributions and hazard functions for simu-
lated cohorts based on atomic bomb survivor data (Fakir
et al. 2009). All these studies analyzed only a single aspect
of progression, early stochastic proliferation of malignant
cells, leading to extinction or clonal growth. We suggest
that more investigations of progression, especially of tumor
dormancy, are needed for the following reasons
1. There is strong evidence that microscopic tumors are
commonly present in adults in the form of dormant
lesions (Black and Welch 1993). In such cases,
progression is presumably delayed or arrested by
nutrient or oxygen deprivation, signals from the
microenvironment and interactions with associated
stromal, immune system, or endothelial cells (Aguirre-
Ghiso 2007).
2. Progression is the one relevant process where exten-
sive human data are directly available. Indeed,
advances in molecular technologies are continuously
providing more insights into the pathology of the
tumors and the process of their development in the
asymptomatic state or after clinical detection (Bunn
2002; Liu et al. 2008). In addition, continuing screen-
ing programs and measurements of sojourn time, the
interval during which the disease does not produce
symptoms leading to diagnosis but is already detect-
able by screening tests, are providing more precise and
quantitative data (Chien and Chen 2008; Chien et al.
2008).
3. Reactivation of dormant lesions occurs after other
perturbations, e.g. surgery (Veronesi et al. 1995;
Udagawa 2008) and trauma (El Saghir et al. 2005;
Naumov et al. 2009). Recurrent cancer following
treatment is reviewed in (Naumov et al. 2008).
Radiation as well can act directly on progression for
example by altering angiogenesis or immune responses
[reviewed, e.g. in (Cunha et al. 2003; Folkman and
Kalluri 2004; Ohuchida et al. 2004)]. Clinical cancer
presentation for radiation-induced reactivation of a
pre-existing dormant neoplasm is likely to occur
earlier than for radiation initiation, promotion, or
transformation. Hence, radiation perturbations of pro-
gression may be especially important both in risk
estimation and for prevention or amelioration
measures.
The two-stage clonal expansion carcinogenesis model
The most commonly used biologically based approach to
quantitative cancer modeling and radiation risk estimation
is the two-stage clonal expansion (TSCE) model (Mool-
gavkar and Venzon 1979; Luebeck and Hazelton 2002).
Here, we analyze radiation-inﬂuenced carcinogenesis with
the TSCE model augmented by a more detailed treatment
of progression.
The TSCE model assumes that cancer results from
normal stem cells after two sequential stages in a process
comprising four steps (Fig. 1a). The steps can be described
as follows. Initiation: a step in which normal stem cells
acquire alterations such as mutations and thereby become
stage 1 cells, referred to as pre-malignant cells. Promotion:
a second step where pre-malignant cells proliferate with a
slight growth advantage over the surrounding normal stem
cells. Transformation: a step in which a pre-malignant cell
acquires an additional alteration and becomes a stage 2 (i.e.
malignant) cell. Progression: a ﬁnal step leading from
malignant cells to clinical cancer. Promotion and progres-
sion may last years or decades, while one initiation or
transformation event is comparatively very rapid. In the
standard TSCE model, progression is often approximated
by a ﬁxed relatively short lag time (5–10 years) (Luebeck
et al. 1999; Moolgavkar and Luebeck 2003; Jacob et al.
2007). Here, we assume instead that progression can be
affected by complex processes involving stochastic cell
dynamics, tissue level systems effects, and intercellular
interactions. Even when more than two stages are assumed,
multi-stage models for radiogenic carcinogenesis usually
assume the last step is automatic. A formalism similar to
our progression model in principle could, and in our
opinion probably should, be used to replace this last step.
Progression: early proliferation of malignant cells
Primary malignant lesions are subject to a stochastic birth–
death process and hence may become extinct soon after
their formation, in which case clinical cancer can only arise
from malignant cells formed later. In a simulation of lung
cancer in atomic bomb survivors, we have previously
shown that progression probability distributions for the lag
time from ﬁrst malignant cell to ﬁrst invasive tumor can
extend to more than 50 years (Fakir et al. 2009). While
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123modeling stochastic growth of malignant cells considerably
improves the understanding of tumor progression, it may
not entirely explain large tumor latency periods and dis-
crepancies between observed microscopic tumors and
clinically observed cancers.
Progression: dormancy and invasiveness
Non-extinct malignant clones or microscopic neoplastic
lesions may persist in an asymptomatic state for years or
decades (Aguirre-Ghiso 2007). This behavior has been
shown for primary malignant tumors, for micrometastases
and for residual disease, after treatment (Udagawa 2008).
A corroboration of these phenomena is the observation that
the frequency of microscopic neoplastic lesions in adults is
much larger than the frequency of invasive cancers (Black
and Welch 1993; Folkman and Kalluri 2004).
These large delays are generally attributed mainly to
tumor dormancy. The speciﬁc features of dormancy may
vary; they depend on the phase in tumor growth and the
underlying mechanisms. In fact, dormancy can be related
to single dormant cells subject to cell cycle arrest or to
microscopic dormant tumors that are in a state of balanced
apoptosis and proliferation resulting in no net increase in
tumor mass (Aguirre-Ghiso 2007; Naumov et al. 2008;
Udagawa 2008). In the second case, dormancy is usually
due to immune suppression or the lack of neovasculariza-
tion (Naumov et al. 2008). In the following, we refer to
dormancy as the phase in the progression step where the
growth of microscopic malignant lesions is inhibited. It can
be considered as a dynamic equilibrium from which tumors
may re-emerge when that equilibrium is disrupted. If the
tumor escapes dormancy, it resumes growing at a net per-
cell growth rate comparable with the pre-dormancy rate
(Naumov et al. 2006b).
Methods
In order to account for accidental extinction of malignant
clones and tumor dormancy, we augmented the TSCE
model (Fig. 1a) with a progression model involving a
sequence of three successive phases (Fig. 1b): 1, early
stochastic proliferation of malignant cells that leads either
to clonal extinction or to dormancy; 2, a stochastic dor-
mancy duration that depends on tumor type and site and
can, in some cases, continue indeﬁnitely; 3, invasiveness
during which the tumor resumes growing and causes the
ﬁrst symptoms. Parameter choices were taken to be those
appropriate for lung adenocarcinomas. We next describe
methods for analyzing these three phases of progression,
then implementation of the augmented model, then the
parameter choices.
Progression phase 1: initial birth–death process
Non-extinct malignant lesions grow ﬁrst exponentially and
homogeneously, being mainly composed of proliferative
cells. Then because of limited resources (number of cap-
illaries in the tissue and oxygen diffusion within the
tumor), some cells may become hypoxic, anoxic, or
necrotic as the volume of the tumor increases (Adam and
Maggelakis 1990). The tumor then shows a certain degree
of heterogeneity in its composition, its growth gradually
slows and its volume converges to a limiting value, usually
called carrying capacity. The growth of tumors is thus
better described by S-shaped curves of non-homogeneous
systems (see e.g. Gyllenberg and Webb 1990; Michelson
and Leith 1997; Sachs et al. 2001; Albano and Giorno
2006). This limited growth may, actually, occur at different
levels of tumor proliferation controlled by a sequential
increase of the carrying capacity. Indeed, Speer et al.
(1984) showed that stepwise growth offers a better repre-
sentation of in vivo data for tumor growth (Speer et al.
1984). In our study, microscopic dormancy is assumed to
be a ﬁrst pause in tumor proliferation. Growth proﬁles at
the macroscopic scale (after clinical presentation) are not
of direct interest here.
normal
cells  promotion
initiation         transformation
clinical
 cancer progression
malignant
cell
dormant
cancer
clone
harmless
stochastic
extinction
clinical
 cancer
suppression invasive
growth
proliferation
Fig. 1 Carcinogenesis steps a the standard two-stage clonal expan-
sion (TSCE) model for overall carcinogenesis. Initiation rapid
alteration that produces a pre-malignant cell from the pool of normal
stem cells; promotion stochastic proliferation of the pre-malignant
cells; transformation a second rapid alteration which generates a
malignant cell from the pool of pre-malignant cells; progression
occurs during the time from the ﬁrst malignant cell to clinical cancer.
b More realistic model of the progression step. After transformation, a
lesion may need to progress through bottlenecks, including stochastic
extinction and/or dormancy, in order to generate a clinical cancer. If
more than one malignant cell is formed by transformation, the
different clones evolve independently of each other. For example, the
second malignant cell could lead to the ﬁrst clinical cancer if the ﬁrst
malignant clone becomes extinct, remains dormant indeﬁnitely, or
happens to grow slowly
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123In our study, tumor growth in phase 1 of progression is
described by a stochastic logistic model with birth rate b(t)
and death rate d(t) given by
bðtÞ¼b0 1  
nðtÞ
C

and dðtÞ¼d0 1  
nðtÞ
C

ð1Þ
where n(t) is a random function representing the number of
cells in a malignant clone; n(t) jumps among various non-
negative integers as the clone grows or shrinks; b0 and d0,
with b0[d0, are positive constants representing the max-
imum birth and death rates, respectively. The positive
constant C in Eq. 1 is the carrying capacity. The carrying
capacity corresponds to the number of cells in a dormant
tumor. In a deterministic formalism n(t) would approach
but never reach C; in the stochastic logistic process n(t)
eventually reaches either values CC (dormant tumor) or 0
(extinction) (Tan 2002).
Progression phase 2: dormancy
Once the number of cells reaches or exceeds the carrying
capacity C, the tumor is here considered dormant and
modeled as a single unit. Dormant tumors are taken to
progress according to a Markov process to permanent
suppression or to invasiveness (escape from growth inhi-
bition). The time of dormancy can then be approximated as
a stochastic variable which follows an exponential distri-
bution that depends on one parameter, the waiting time.
The waiting time is determined by angiogenesis, immune
system interactions, the tumor location, and other factors.
Progression phase 3: invasion
The growth of the invasive state is taken to be determin-
istic, an approximation valid to high accuracy in view of
the large number of cells at this stage. The growth time
from a dormant lesion to a clinically observable tumor is
approximated using a simple exponential growth model.
Implementation of the augmented model
The TSCE model is implemented by Monte-Carlo instead
of analytic methods, in order to ﬁt smoothly with the
Monte-Carlo progression calculations. The Monte Carlo
program, based on earlier work (Fakir et al. 2009), simu-
lates the full stochastic carcinogenesis process, including
progression analyzed with our stochastic progression
model described previously. Radiation is represented by an
additive instantaneous dose-linear initiation term. Thus, the
initiation rate is expressed as aIðtÞ¼aIB þ aIRDdðt   eÞ,
where aIB is an adjustable background initiation rate con-
stant, aIR is an adjustable constant representing the initia-
tion probability per unit radiation dose, D is the radiation
dose, e is age at exposure, and d(t - e)is the Dirac delta
function. We did not explicitly consider more complex
models where radiation acts also on promotion, transfor-
mation or progression itself because the model with radi-
ation only perturbing initiation already gives considerable
insight into the later progression mechanisms of interest.
The Monte Carlo progression calculation proceeds in
small steps of size Dt. For phase 1 of progression, the
numbers of births and deaths during Dt are generated from
a multinomial distribution with probabilities b(t)Dt and
d(t)Dt, respectively. If a tumor then reaches dormancy, it is
added to the pool of dormant tumors. At each time step Dt,
a multinomial distribution is used to select the numbers of
permanently suppressed and reactivated dormant tumors
with probabilities aDt and bDt, respectively. Finally, if a
dormant tumor is reactivated, its subsequent growth is
modeled simply as exponential growth up to a macroscopic
or clinically observable size. Fig. 2 displays the transition
parameters and growth rates of the progression step.
Parameter values
The simulated cohort contains 10
5 individuals. Based on
measurements of Mercer et al. (1994), we assume that the
number of stem cells (basal and secretory) in the lung is
4 9 10
9. Their birth rate is assumed equal to 12 per year
(NRC 1999). A tumor may give rise to the ﬁrst symptoms
and be ﬁrst diagnosed at volume of *1 ccm that contains
*10
9 cells (Friberg and Mattson 1997). It is assumed here
that lung cancer behaves totally as lung adenocarcinoma.
Growth kinetics and volume doubling time have been
measured in vivo for early stage lung adenocarcinoma
Fig. 2 Progression parameters. The ﬁgure shows the same boxes as
in Fig. 1b, specifying the clone states that are used in our model to
analyze progression processes. Labels on the arrows specify the
parameters relevant to transitions between these states. The param-
eters are ﬁxed by experimental (not epidemiological) data and are
described in more detail in the Methods section. The transition from a
malignant cell to a harmless clone (shown by the downward arrow;i t
is actually an extinct clone in this case) is governed mainly by the
maximum death rate d0 and birth rate b0, with carrying capacity C
playing almost no role. In the transition from dormant tumor to
clinical cancer, only the difference SGR
: b0 - d0 is relevant, not b0
and d0 seperately. In our calculations here, a was taken as 0
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123using low-dose spiral computed tomography by Wang and
colleagues (Wang et al. 2000). However, Mehrara et al.
(2007) have shown that the speciﬁc growth rate (SGR) is a
more suitable quantity for the description of tumor growth
kinetics. The SGR represents the volume growth rate of the
tumor in an exponential growth model. The corresponding
SGR is equal to 2.37 per year (Mehrara et al. 2007). This
growth rate implies that exponential deterministic growth
of a malignant cell would produce a clinical cancer in
about 8.7 years. It has been suggested that tumor growth is
due to a reduction in cell loss, while birth rates remain
similar in normal tissues and tumors (Rew and Wilson
2000). Accordingly, it is assumed here that tumor growth is
due to a reduction in cell death rates, while birth rates
remain similar to the birth rates in normal tissues. There-
fore, the death rate d0 for lung adenocarcinomas is 9.63 per
year. A dormant tumor is generally assumed to have a
diameter of *1 mm, and the number of cells equal to
approximately 10
6 (Naumov et al. 2006a). Despite a sub-
stantial literature about tumor dormancy, very few papers
present quantitative data about dormancy in human cancer.
For simplicity, we here set the permanent suppression rate,
a, to 0. The rate of invasiveness, b, is set equal to 0.26 per
year based on a mean sojourn time (MST) for lung cancer
equal to 3.9 years (95% CI: 3.42–3.99) (Chien and Chen
2008). The MST represents the average duration of the
preclinical screen detectable phase. The data on which the
calculation of the MST is based consist of a large screening
study of asymptomatic individuals at risk for lung cancer
using low-dose computed tomography (Henschke et al.
2006). Following our earlier discussion, we assume that
tumors grow with the same rate before and after dormancy.
The time between the reactivation of dormant tumors and
clinically observable tumors is then 2.9 years based on a
deterministic exponential growth with a SGR equal to 2.37
per year. Progression is thus characterized in our study by
independently measured tumor growth kinetics and
involves no parameters that can be adjusted to ﬁt epide-
miological data. In contrast, in more standard versions of
the TSCE model only one progression parameter, the lag
time, is used but this parameter is adjusted to the epide-
miological data.
The remaining parameters are those of the standard
TSCE model and were determined in order to have the
overall model reproduce lung cancer data for atomic bomb
survivors based on the most recent life span study (LSS)
1958–1998 (Preston et al. 2007). The purpose of using the
LSS data was not to give optimal ﬁts to the atomic bomb
survivor data but rather to obtain a set of reasonable
parameters with which to analyze the properties of the
progression step in an overall, combined model. Detailed
descriptions of the cohort simulation procedure and the
analysis methods are given in (Fakir et al. 2009). The
adjusted TSCE parameter values are the spontaneous ini-
tiation rate aIB = 9.5 9 10
-11 year
-1, the radiation initi-
ation rate aIR = 8 9 10
-8 G year
-1, the transformation
rate aT = 3.9 9 10
-6 year
-1, and birth and death rates of
pre-malignant cells, bP and dP, which are 12 and
11.85 year
-1, respectively. In our case, all these parame-
ters are in principle separately identiﬁable.
Results
In the simulated cohort, only 51% of the individuals who
developed at least one malignant cell presented clinical
cancers. Figure 3 shows the incidence probabilities for
both the ﬁrst malignant cells and clinical cancers. At early
and middle ages individuals are more likely to build up
malignant clones that may or may not continue through all
the progression phases. Later the persistent lesions show
clinical cancers, while the probability of producing a
malignant cell for the ﬁrst time decreases. A clinical cancer
incident at 70 years for instance may have resulted from a
malignant cell that has been produced at an age of
20 years.
In order to compare our stochastic progression model to
the deterministic approximation, we calculated the lag time
distributions from the ﬁrst malignant transformation to
clinical cancer (Fig. 4). For stochastic-exponential growth
without dormancy, the ﬁrst peak represents the cases where
the ﬁrst malignant cell escaped stochastic extinction and
progressed to the clinical (symptomatic) phase. For sto-
chastic-logistic growth followed by dormancy, the ﬁrst
peak represents cases where the ﬁrst malignant cells pro-
duced escaped stochastic extinction and had only short
dormancy. The width of the ﬁrst peak depends on the birth
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Fig. 3 Probability density distributions of time of ﬁrst occurrence of
primary malignant cells and clinical tumors in a heterogeneous cohort
mimicking the atomic bomb survivor cohort. Competing risks are not
taken into account. Tumor growth parameters correspond to lung
adenocarcinoma. The other parameters are adjusted in order to
simulate clinically observed lung cancer incidence. Fluctuations are
due to using Monte-Carlo methods
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123and death rates, and its location represents the mean time
needed for proliferation (for exponential growth) or pro-
liferation plus escaping dormancy plus post-dormancy
exponential growth (for logistic growth). The broader,
second peak represents cases where the ﬁrst malignant
clone becomes extinct and clinical cancers are generated
from a malignant cell produced later. Dormancy shifts the
distribution by about 6 years and considerably ﬂattens it.
The difference in distributions between the solely expo-
nential growth and the growth with dormancy is due to
three components: the logistic growth model, the dormancy
period and the deterministic re-growth period after
‘‘awakening’’ from dormancy. The logistic shape has only
a minor effect on the latency period. The six-year shift is
mainly due to the dormancy period (mean 3.9 years) and
the deterministic re-growth (2.9 years). As discussed in our
earlier work (Fakir et al. 2009), variations in the rates for
processes that precede progression (i.e. initiation, promo-
tion and transformation rates) may indirectly but signiﬁ-
cantly affect our estimated lag time distributions due to the
way in which we ﬁt the epidemiological data. Figure 4
shows the substantial effect of varying a promotion
parameter, the death rate dP of pre-malignant cells. In
contrast, the lag time distributions don’t show any signiﬁ-
cant dependence on the background initiation rate (results
not shown here).
For speciﬁc exposure conditions and parameter values, it
is of interest to calculate the frequency distributions of
tumors for an individual at a given age. Such distributions
may be useful for studying potential effects of environ-
mental factors on progression, and especially on malignant
microscopic disease and its evolution into symptomatic
cancer. As an illustration, Fig. 5 shows the frequency dis-
tributions of malignant transformations and clinical
symptomatic tumors for age 90 based on the present
parameters. In our example, it is found that by age 90 an
individual who has never developed a clinical cancer has
on average developed 48 separate malignant transforma-
tions but would present only 1.2 dormant tumors.
Conclusion
In many calculations of radiation risks using the TSCE
model, the production of the ﬁrst malignant cell inevitably
gives cancer after a ﬁxed lag time. Some studies have
addressed the issues of progression and the ﬁxed lag time
assumption. For instance, Hazelton et al. have analyzed
progression in the TSCE model by replacing the ﬁxed lag
time by a gamma distribution that considerably improved
risk estimation and predicted larger lag times (Hazelton
et al. 2001; 2006). In our work, we aimed to give a bio-
logically motivated quantitative description of the pro-
gression step, involving tumor proliferation mechanisms
and observed phenomena. We aimed to help bridge the gap
between radiation biology modeling based on experimental
and epidemiological studies, and the clinical aspects of
carcinogenesis: at present clinical observations tell us more
about progression than about earlier carcinogenesis steps.
Here, we argued that the progression step and the ability
of malignant cells to proliferate, escape extinction, and
escape dormancy are at least as important as the earlier
steps. Progression may constitute a much larger portion of
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Fig. 4 Stochastic progression lag time distributions (ﬁrst malignant
cell to ﬁrst clinical tumor) for two values of the pre-malignant cell
death rate dp. For comparison, the ﬁgure also shows the lag time
distribution when stochastic exponential malignant cell proliferation
without dormancy is assumed and shows the delta-function distribu-
tion for a 10-year deterministic lag time model. Tumor growth
parameters during progression correspond to lung adenocarcinoma;
for other kinds of lung cancer (results shown in [Fakir et al. (2009) but
not in the present paper] the ﬁrst peak of the curve assuming no
dormancy is considerably further to the left. The parameters for
earlier steps (initiation, promotion, and transformation) are adjusted
in order to simulate lung cancer incidence in atomic bomb survivors
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Fig. 5 Predicted distribution of the number of malignant transfor-
mations and of clinical tumors that occur in the lifetime of a non-
irradiated individual of age 90 years assuming the parameters
computed here and no competing risks
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123the evolution time of cancer than is often assumed in
radiobiological models. In agreement with observations,
our model predicts that an individual may contain a sig-
niﬁcant number of dormant tumors.
Other calculations (not shown here), e.g. for faster
growing tumors, give somewhat smaller progression times
(Fakir et al. 2009). However, in view of the long pro-
gression times estimated here, the data on timing of extra
cancers in the atomic bomb survivors and on radiotherapy
patients (Little et al. 1999; Preston et al. 2007) indicate that
radiation probably acts directly on promotion, on trans-
formation, and even on progression itself. If radiation
action was conﬁned to initiation in Fig. 1a, there would not
be enough time for the extra radiogenic lesions to go
through the subsequent phases prior to observed extra
clinical cancers. Instead, clinical cancers that appear within
*10 years of the irradiation may result from reactivation
of dormant tumors, other progression acceleration, or
malignant transformation of already present pre-malignant
cells that then undergo a comparatively rapid progression
(the ﬁrst peak in Fig. 4). If conﬁrmed, radiation action
directly on progression would have major implications for
radiation risk estimation and protective measures.
Incorporating progression details complicates the anal-
ysis of cancer development (Enderling et al. 2009) and
introduces additional parameters. Hence, interdisciplinary
studies are needed to better comprehend the different
aspects of the problem. Cancer screening studies can give
valuable information about carcinogenesis. Studies of
second cancers after fractionated radiotherapy are done
under controlled exposure conditions and with good
knowledge of tumor incidence in each patient. Autopsies
can uncover microscopic tumors. Such clinical studies can
supplement the usual analyses of radiogenic carcinogene-
sis, based on data from in vitro or animal experiments and
epidemiological data (on atomic bomb survivors and
occupationally or environmentally exposed cohorts). The
clinical data are relevant to later steps of carcinogenesis,
especially progression. Thus, epidemiological data, the
possibility of radiation inﬂuencing progression, and the
need to incorporate increasingly available clinical data all
point to the importance of considering detailed progression
scenarios in mathematical/computational carcinogenesis
modeling.
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